Table 1 Clinical characteristics of LUAD patients in the testing and training groups
Covariates | Type | Total n(%) | Group n(%) | P-value | |
|---|---|---|---|---|---|
Testing | Training | ||||
Age (years) |  <  = 65 | 232(47.06%) | 120(48.78%) | 112(45.34%) | 0.5527 |
|  |  > 65 | 251(50.91%) | 122(49.59%) | 129(52.23%) |  |
| Â | unknow | 10(2.03%) | 4(1.63%) | 6(2.43%) | Â |
Gender | female | 264(53.55%) | 130(52.85%) | 134(54.25%) | 0.8239 |
| Â | male | 229(46.45%) | 116(47.15%) | 113(45.75%) | Â |
Tumor Stage | I | 265(53.75%) | 134(54.47%) | 131(53.04%) | 0.8863 |
| Â | II | 116(23.53%) | 60(24.39%) | 56(22.67%) | Â |
| Â | III | 79(16.02%) | 38(15.45%) | 41(16.6%) | Â |
| Â | IV | 25(5.07%) | 11(4.47%) | 14(5.67%) | Â |
| Â | unknow | 8(1.62%) | 3(1.22%) | 5(2.02%) | Â |
Stage | |||||
 T | T1 | 164(33.27%) | 71(28.86%) | 93(37.65%) | 0.1079 |
| Â | T2 | 265(53.75%) | 143(58.13%) | 122(49.39%) | Â |
| Â | T3 | 43(8.72%) | 19(7.72%) | 24(9.72%) | Â |
| Â | T4 | 18(3.65%) | 11(4.47%) | 7(2.83%) | Â |
| Â | unknow | 3(0.61%) | 2(0.81%) | 1(0.4%) | Â |
 M | M0 | 327(66.33%) | 159(64.63%) | 168(68.02%) | 0.9582 |
| Â | M1 | 24(4.87%) | 11(4.47%) | 13(5.26%) | Â |
| Â | unknow | 142(28.8%) | 76(30.89%) | 66(26.72%) | Â |
 N | N0 | 319(64.71%) | 161(65.45%) | 158(63.97%) | 0.3212 |
| Â | N1 | 93(18.86%) | 50(20.33%) | 43(17.41%) | Â |
| Â | N2 | 68(13.79%) | 30(12.2%) | 38(15.38%) | Â |
| Â | N3 | 2(0.41%) | 0(0%) | 2(0.81%) | Â |
| Â | unknow | 11(2.23%) | 5(2.03%) | 6(2.43%) | Â |